Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 9393-9413

  Hewings, David S ^a,b   Rooney, Timothy P C ^a,b   Jennings, Laura E ^a,b   Hay, Duncan A ^a,b   Schofield, Christopher J ^a   Brennan, Paul E ^b   Knapp, Stefan ^b   Conway, Stuart J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 ARYL 3,5 DIEMTHYLISOXAZOLE; ALPRAZOLAM; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BET INHIBITOR; BIC 1; BROMODOMAIN CONTAINING PROTEIN; CYTOKINE; DIAZEPINE DERIVATIVE; ENDOTOXIN; GSK 525762 A; GSK 525762A; GW 841819 X; GW 841819X; HISTONE ACETYLTRANSFERASE PCAF; ISOXAZOLE DERIVATIVE; JQ 1; LIGAND; LIPOPOLYSACCHARIDE; LYSINE DERIVATIVE; MIDAZOLAM; N ACETYLLYSINE; PROTEIN; QUINOLINE DERIVATIVE; TAT KAC50 PEPTIDE; TRANSACTIVATOR PROTEIN; TRIAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACETYLATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CRYSTAL STRUCTURE; CYTOKINE RELEASE; DRUG DESIGN; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HYDROPHOBICITY; IC 50; MOLECULAR BIOLOGY; MOLECULAR PROBE; MOLECULE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOPHORE; PHYLOGENY; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REVIEW; SEPTIC SHOCK; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; X RAY CRYSTALLOGRAPHY;

ACETYLATION; ANIMALS; HISTONES; HUMANS; LYSINE; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84870013141     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300915b     Document Type: Review

References (88)

1. Kouzarides, T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 2000, 19, 1176-1179
2. Choudhary, C.; Kumar, C.; Gnad, F.; Nielsen, M. L.; Rehman, M.; Walther, T. C.; Olsen, J. V.; Mann, M. Lysine acetylation targets protein complexes and co-regulates major cellular functions Science 2009, 325, 834-840
3. Weinert, B. T.; Wagner, S. A.; Horn, H.; Henriksen, P.; Liu, W. R.; Olsen, J. V.; Jensen, L. J.; Choudhary, C. Proteome-wide mapping of the Drosophila acetylome demonstrates a high degree of conservation of lysine acetylation Sci. Signaling 2011, 4, ra48
4. Allfrey, V.; Faulkner, R.; Mirsky, A. Acetylation and methylation of histones and their possible role in regulation of RNA synthesis Proc. Natl. Acad. Sci. U.S.A. 1964, 51, 786-794
5. Winston, F.; Allis, C. The bromodomain: a chromatin-targeting module? Nat. Struct. Biol. 1999, 6, 601-604
6. Strahl, B. D.; Allis, C. D. The language of covalent histone modifications Nature 2000, 403, 41-45
7. Jenuwein, T.; Allis, C. D. Translating the histone code Science 2001, 293, 1074-1080
8. Agalioti, T.; Chen, G.; Thanos, D. Deciphering the transcriptional histone acetylation code for a human gene Cell 2002, 111, 381-392
9. Loyola, A.; Almouzni, G. Bromodomains in living cells participate in deciphering the histone code Trends Cell Biol. 2004, 14, 279-281
10. Gardner, K. E.; Allis, C. D.; Strahl, B. D. Operating on chromatin, a colorful language where context matters J. Mol. Biol. 2011, 409, 36-46
11. Biel, M.; Wascholowski, V.; Giannis, A. Epigenetics - an epicenter of gene regulation: histones and histone-modifying enzymes Angew. Chem., Int. Ed. 2005, 44, 3186-3216
12. Holliday, R. Epigenetics: a historical overview Epigenetics 2006, 1, 76-80
13. Probst, A. V.; Dunleavy, E.; Almouzni, G. Epigenetic inheritance during the cell cycle Nat. Rev. Mol. Cell Biol. 2009, 10, 192-206
14. Sippl, W.; Jung, M. Epigenetic drug discovery special issue Bioorg. Med. Chem. 2011, 19, 3603-3604
15. Arrowsmith, C. H.; Bountra, C.; Fish, P. V.; Lee, K.; Schapira, M. Epigenetic protein families: a new frontier for drug discovery Nat. Rev. Drug Discovery 2012, 11, 384-400
16. Dhalluin, C.; Carlson, J. E.; Zeng, L.; He, C.; Aggarwal, A. K.; Zhou, M. M. Structure and ligand of a histone acetyltransferase bromodomain Nature 1999, 399, 491-496
17. Zeng, L.; Zhou, M. Bromodomain: an acetyl-lysine binding domain FEBS Lett. 2002, 513, 124-128
18. Filippakopoulos, P.; Knapp, S. The bromodomain interaction module FEBS Lett. 2012, 586, 2692-2704
19. Nakamura, T.; Liu, Y.-J.; Nakashima, H.; Umehara, H.; Inoue, K.; Matoba, S.; Tachibana, M.; Ogura, A.; Shinkai, Y.; Nakano, T. PGC7 binds histone H3K9me2 to protect against conversion of 5mC to 5hmC in early embryos Nature 2012, 486, 415-419
20. Duvic, M.; Vu, J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma Expert Opin. Invest. Drugs 2007, 16, 1111-1120
21. Bertino, E. M.; Otterson, G. A. Romidepsin: a novel histone deacetylase inhibitor for cancer Expert Opin. Invest. Drugs 2011, 20, 1151-1158
22. Adachi, K.; Hikawa, H.; Hamada, M.; Endoch, J.-I.; Ishibichi, S.; Fujie, N.; Tanaka, M.; Sugahara, K.; Oshita, K.; Murata, M. Thienotriazolodiazepine Compound and a Medicinal Use Thereof. PCT/JP2006/310709 (WO/2006/129623), 2006.
23. Miyoshi, S.; Ooike, S.; Iwata, K.; Hikawa, H.; Sugahara, K. Antitumor Agent. PCT/JP2008/073864 (WO/2009/084693), 2009.
24. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E. Selective inhibition of BET bromodomains Nature 2010, 468, 1067-1073
25. Nicodeme, E.; Jeffrey, K. L.; Schaefer, U.; Beinke, S.; Dewell, S.; Chung, C.-W.; Chandwani, R.; Marazzi, I.; Wilson, P.; Coste, H.; White, J.; Kirilovsky, J.; Rice, C. M.; Lora, J. M.; Prinjha, R. K.; Lee, K.; Tarakhovsky, A. Suppression of inflammation by a synthetic histone mimic Nature 2010, 468, 1119-1123
26. Zuber, J.; Shi, J.; Wang, E.; Rappaport, A. R.; Herrmann, H.; Sison, E. A.; Magoon, D.; Qi, J.; Blatt, K.; Wunderlich, M.; Taylor, M. J.; Johns, C.; Chicas, A.; Mulloy, J. C.; Kogan, S. C.; Brown, P.; Valent, P.; Bradner, J. E.; Lowe, S. W.; Vakoc, C. R. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Nature 2011, 478, 524-528
27. Mertz, J. A.; Conery, A. R.; Bryant, B. M.; Sandy, P.; Balasubramanian, S.; Mele, D. A.; Bergeron, L.; Sims, R. J. Targeting MYC dependence in cancer by inhibiting BET bromodomains Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 16669-16674
28. Dawson, M. A.; Prinjha, R. K.; Dittmann, A.; Giotopoulos, G.; Bantscheff, M.; Chan, W.-I.; Robson, S. C.; Chung, C.-W.; Hopf, C.; Savitski, M. M.; Huthmacher, C.; Gudgin, E.; Lugo, D.; Beinke, S.; Chapman, T. D.; Roberts, E. J.; Soden, P. E.; Auger, K. R.; Mirguet, O.; Doehner, K.; Delwel, R.; Burnett, A. K.; Jeffrey, P.; Drewes, G.; Lee, K.; Huntly, B. J. P.; Kouzarides, T. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Nature 2011, 478, 529-533
29. Delmore, J. E.; Issa, G. C.; Lemieux, M. E.; Rahl, P. B.; Shi, J.; Jacobs, H. M.; Kastritis, E.; Gilpatrick, T.; Paranal, R. M.; Qi, J.; Chesi, M.; Schinzel, A. C.; McKeown, M. R.; Heffernan, T. P.; Vakoc, C. R.; Bergsagel, P. L.; Ghobrial, I. M.; Richardson, P. G.; Young, R. A.; Hahn, W. C.; Anderson, K. C.; Kung, A. L.; Bradner, J. E.; Mitsiades, C. S. BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 2011, 146, 904-917
30. GlaxoSmithKline. Protocol Summary for 115521. http://www.gsk- clinicalstudyregister.com/protocol-detail.jsp?protocolId=115521&studyId= 8CA80D1C-BFAC-4309-9EA7-9F65BC8197A2&compound=115521&type= GSK+Study+ID&letterrange=All.
31. Muller, S.; Filippakopoulos, P.; Knapp, S. Bromodomains as therapeutic targets Expert Rev. Mol. Med. 2011, 13, e29
32. Furdas, S. D.; Carlino, L.; Sippl, W.; Jung, M. Inhibition of bromodomain-mediated protein-protein interactions as a novel therapeutic strategy Med. Chem. Commun. 2012, 3, 123-134
33. Prinjha, R. K.; Witherington, J.; Lee, K. Place your BETs: the therapeutic potential of bromodomains Trends Pharmacol. Sci. 2012, 33, 146-153
34. Chung, C.-W.; Tough, D. F. Bromodomains: a new target class for small molecule drug discovery. Drug Discovery Today: Ther. Strategies [Online early access]. DOI: 10.1016/j.ddstr.2011.12.002. Published Online: Jan 28, 2012.
35. Conway, S. J. Bromodomains: Are readers right for epigenetic therapy? ACS Med. Chem. Lett. [Online early access]. DOI: 10.1021/ml300221t. Published Online: Aug 9, 2012
36. Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T.; Lambert, J.-P.; Barsyte-Lovejoy, D.; Felletar, I.; Volkmer, R.; Muller, S.; Pawson, T.; Gingras, A.-C.; Arrowsmith, C. H.; Knapp, S. Histone recognition and large-scale structural analysis of the human bromodomain family Cell 2012, 149, 214-231
37. Tamkun, J. W.; Deuring, R.; Scott, M. P.; Kissinger, M.; Pattatucci, A. M.; Kaufman, T. C.; Kennison, J. A. brahma: a regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2 Cell 1992, 68, 561-572
38. Haynes, S. R.; Dollard, C.; Winston, F.; Beck, S.; Trowsdale, J.; Dawid, I. B. The bromodomain: a conserved sequence found in human, Drosophila and yeast proteins Nucleic Acids Res. 1992, 20, 2603
39. Mujtaba, S.; Zeng, L.; Zhou, M. M. Structure and acetyl-lysine recognition of the bromodomain Oncogene 2007, 26, 5521-5527
40. Vollmuth, F.; Blankenfeldt, W.; Geyer, M. Structures of the dual bromodomains of the P-TEFb-activating protein Brd4 at atomic resolution J. Biol. Chem. 2009, 284, 36547-36556
41. Chung, C.-W.; Witherington, J. Progress in the discovery of small-molecule inhibitors of bromodomain-histone interactions J. Biomol. Screening 2011, 16, 1170-1185
42. Chung, C.-W. Small molecule bromodomain inhibitors: extending the druggable genome Prog. Med. Chem. 2012, 51, 1-55
43. Brennan, P.; Filippakopoulos, P.; Knapp, S. The therapeutic potential of acetyl-lysine and methyl-lysine effector domains. Drug Discovery Today: Ther. Strategies [Online early access]. DOI: 10.1016/j.ddstr.2012.04.001. Published Online: May 18, 2012.
44. Bunnage, M. E. Getting pharmaceutical R&D back on target Nat. Chem. Biol. 2011, 7, 335-339
45. Mujtaba, S.; He, Y.; Zeng, L.; Farooq, A.; Carlson, J. E.; Ott, M.; Verdin, E.; Zhou, M.-M. Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain Mol. Cell 2002, 9, 575-586
46. Zeng, L.; Li, J.; Muller, M.; Yan, S.; Mujtaba, S.; Pan, C.; Wang, Z.; Zhou, M.-M. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association J. Am. Chem. Soc. 2005, 127, 2376-2377
47. Dorr, A.; Kiermer, V.; Pedal, A.; Rackwitz, H.-R.; Henklein, P.; Schubert, U.; Zhou, M.-M.; Verdin, E.; Ott, M. Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain EMBO J. 2002, 21, 2715-2723
48. Pan, C.; Mezei, M.; Mujtaba, S.; Muller, M.; Zeng, L.; Li, J.; Wang, Z.; Zhou, M.-M. Structure-guided optimization of small molecules inhibiting human immunodeficiency virus 1 Tat association with the human coactivator p300/CREB binding protein-associated factor J. Med. Chem. 2007, 50, 2285-2288
49. Chung, C.-W.; Coste, H.; White, J. H.; Mirguet, O.; Wilde, J.; Gosmini, R. L.; Delves, C.; Magny, S. M.; Woodward, R.; Hughes, S. A.; Boursier, E. V.; Flynn, H.; Bouillot, A. M.; Bamborough, P.; Brusq, J.-M. G.; Gellibert, F. J.; Jones, E. J.; Riou, A. M.; Homes, P.; Martin, S. L.; Uings, I. J.; Toum, J.; Clément, C. A.; Boullay, A.-B.; Grimley, R. L.; Blandel, F. M.; Prinjha, R. K.; Lee, K.; Kirilovsky, J.; Nicodeme, E. Discovery and characterization of small molecule inhibitors of the BET family bromodomains J. Med. Chem. 2011, 54, 3827-3838
50. Filippakopoulos, P.; Picaud, S.; Fedorov, O.; Keller, M.; Wrobel, M.; Morgenstern, O.; Bracher, F.; Knapp, S. Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family Bioorg. Med. Chem. 2012, 20, 1878-1886
51. Zhang, G.; Liu, R.; Zhong, Y.; Plotnikov, A. N.; Zhang, W.; Zeng, L.; Rusinova, E.; Gerona-Nevarro, G.; Moshkina, N.; Joshua, J.; Chuang, P. Y.; Ohlmeyer, M.; He, J. C.; Zhou, M.-M. Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition J. Biol. Chem. 2012, 287, 28840-28851
52. Hewings, D. S.; Wang, M.; Philpott, M.; Fedorov, O.; Uttarkar, S.; Filippakopoulos, P.; Picaud, S.; Vuppusetty, C.; Marsden, B.; Knapp, S.; Conway, S. J.; Heightman, T. D. 3,5-Dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands J. Med. Chem. 2011, 54, 6761-6770
53. Bamborough, P.; Diallo, H.; Goodacre, J. D.; Gordon, L.; Lewis, A.; Seal, J. T.; Wilson, D. M.; Woodrow, M. D.; Chung, C.-W. Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides J. Med. Chem. 2012, 55, 587-596
54. Mirguet, O.; Lamotte, Y.; Donche, F.; Toum, J.; Gellibert, F.; Bouillot, A.; Gosmini, R.; Nguyen, V.-L.; Delannée, D.; Seal, J.; Blandel, F.; Boullay, A.-B.; Boursier, E.; Martin, S.; Brusq, J.-M.; Krysa, G.; Riou, A.; Tellier, R.; Costaz, A.; Huet, P.; Dudit, Y.; Trottet, L.; Kirilovsky, J.; Nicodeme, E. From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151 Bioorg. Med. Chem. Lett. 2012, 22, 2963-2967
55. Seal, J.; Lamotte, Y.; Donche, F.; Bouillot, A.; Mirguet, O.; Gellibert, F.; Nicodeme, E.; Krysa, G.; Kirilovsky, J.; Beinke, S.; McCleary, S.; Rioja, I.; Bamborough, P.; Chung, C.-W.; Gordon, L.; Lewis, T.; Walker, A. L.; Cutler, L.; Lugo, D.; Wilson, D. M.; Witherington, J.; Lee, K.; Prinjha, R. K. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A) Bioorg. Med. Chem. Lett. 2012, 22, 2968-2972
56. Ito, T.; Umehara, T.; Sasaki, K.; Nakamura, Y.; Nishino, N.; Terada, T.; Shirouzu, M.; Padmanabhan, B.; Yokoyama, S.; Ito, A.; Yoshida, M. Real-time imaging of histone h4k12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors Chem. Biol. 2011, 18, 495-507
57. DeMont, E. H.; Gosmini, R. L. Tetrahydroquinolines Derivatives as Bromodomain Inhibitors. EP2010/066701 (WO/2011/054848), 2011.
58. Westwood, N. J. Chemical genetics: how does it function? Philos. Trans. R. Soc. London, Ser. A 2004, 362, 2761-2774
59. Knight, Z. A.; Shokat, K. M. Chemical genetics: where genetics and pharmacology meet Cell 2007, 128, 425-430
60. Krugmann, S.; Anderson, K. E.; Ridley, S. H.; Risso, N.; McGregor, A.; Coadwell, J.; Davidson, K.; Eguinoa, A.; Ellson, C. D.; Lipp, P.; Manifava, M.; Ktistakis, N.; Painter, G.; Thuring, J. W.; Cooper, M. A.; Lim, Z.-Y.; Holmes, A. B.; Dove, S. K.; Michell, R. H.; Grewal, A.; Nazarian, A.; Erdjument-Bromage, H.; Tempst, P.; Stephens, L. R.; Hawkins, P. T. Identification of ARAP3, a novel PI3K effector regulating both Arf and Rho GTPases, by selective capture on phosphoinositide affinity matrices Mol. Cell 2002, 9, 95-108
61. Conway, S. J.; Gardiner, J.; Grove, S. J. A.; Johns, M. K.; Lim, Z.-Y.; Painter, G. F.; Robinson, D. E. J. E.; Schieber, C.; Thuring, J. W.; Wong, L. S.-M.; Yin, M.-X.; Burgess, A. W.; Catimel, B.; Hawkins, P. T.; Ktistakis, N. T.; Stephens, L. R.; Holmes, A. B. Synthesis and biological evaluation of phosphatidylinositol phosphate affinity probes Org. Biomol. Chem. 2010, 8, 66-76
62. Philpott, M.; Yang, J.; Tumber, T.; Fedorov, O.; Uttarkar, S.; Filippakopoulos, P.; Picaud, S.; Keates, T.; Felletar, I.; Ciulli, A.; Knapp, S.; Heightman, T. D. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery Mol. BioSyst. 2011, 7, 2899-2908
63. Vollmuth, F.; Geyer, M. Interaction of propionylated and butyrylated histone H3 lysine marks with Brd4 bromodomains Angew. Chem., Int. Ed. 2010, 49, 6768-6772
64. Molander, G. A.; Canturk, B.; Kennedy, L. E. Scope of the Suzuki-Miyaura cross-coupling reactions of potassium heteroaryltrifluoroborates J. Org. Chem. 2009, 74, 973-980
65. Fall, Y.; Reynaud, C.; Doucet, H.; Santelli, M. Ligand-free-palladium- catalyzed direct 4-arylation of isoxazoles using aryl bromides Eur. J. Org. Chem. 2009, 4041-4050
66. Chung, C.-W.; Dean, A. W.; Woolven, J. M.; Bamborough, P. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery J. Med. Chem. 2012, 55, 576-586
67. Mertz, J. A.; Conery, A. R.; Bryant, B. M.; Sandy, P.; Balasubramanian, S.; Mele, D. A.; Bergeron, L.; Sims, R. J. Targeting MYC dependence in cancer by inhibiting BET bromodomains Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 16669-16674
68. Watson, J. D. Curing "incurable" cancer Cancer Discovery 2011, 1, 477-480
69. Huang, B.; Yang, X.-D.; Zhou, M.-M.; Ozato, K.; Chen, L.-F. Brd4 coactivates transcriptional activation of NFf-kappa B via specific binding to acetylated RelA Mol. Cell. Biol. 2009, 29, 1375-1387
70. Palermo, R. D.; Webb, H. M.; West, M. J. RNA polymerase II stalling promotes nucleosome occlusion and pTEFb recruitment to drive immortalization by Epstein-Barr virus PLoS Pathog. 2011, 7, e1002334
71. Zhao, R.; Nakamura, T.; Fu, Y.; Lazar, Z.; Spector, D. L. Gene bookmarking accelerates the kinetics of post-mitotic transcriptional re-activation Nat. Cell Biol. 2011, 13, 1295-1304
72. Lamonica, J.; Deng, W.; Kadauke, S.; Campbell, A.; Gamsjaeger, R.; Wang, H.; Cheng, Y.; Billin, A.; Hardison, R.; Mackay, J.; Blobel, G. Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes Proc. Natl. Acad. Sci. U.S.A. 2011, 108, E159-E168
73. Devaiah, B. N.; Lewis, B. A.; Cherman, N.; Hewitt, M. C.; Albrecht, B. K.; Robey, P. G.; Ozato, K.; Sims, R. J.; Singer, D. S. BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA polymerase II carboxy-terminal domain Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 6927-6932
74. Chrivia, J.; Kwok, R.; Lamb, N.; Hagiwara, M.; Montminy, M.; Goodman, R. Phosphorylated CREB binds specifically to the nuclear-protein CBP Nature 1993, 365, 855-859
75. Wang, L.; Tang, Y.; Cole, P. A.; Marmorstein, R. Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: implications for histone acetyltransferase evolution and function Curr. Opin. Struct. Biol. 2008, 18, 741-747
76. Bannister, A. J.; Kouzarides, T. The CBP co-activator is a histone acetyltransferase Nature 1996, 384, 641-643
77. Ogryzko, V. V.; Schiltz, R. L.; Russanova, V.; Howard, B. H.; Nakatani, Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases Cell 1996, 87, 953-959
78. Bedford, D. C.; Kasper, L. H.; Fukuyama, T.; Brindle, P. K. Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases Epigenetics 2010, 5, 9-15
79. Ito, A.; Lai, C.; Zhao, X.; Saito, S.; Hamilton, M.; Appella, E.; Yao, T. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2 EMBO J. 2001, 20, 1331-1340
80. Scolnick, D.; Chehab, N.; Stavridi, E.; Lien, M.; Caruso, L.; Moran, E.; Berger, S.; Halazonetis, T. CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein Cancer Res. 1997, 57, 3693-3696
81. Liu, L.; Scolnick, D.; Trievel, R.; Zhang, H.; Marmorstein, R.; Halazonetis, T.; Berger, S. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage Mol. Cell Biol. 1999, 19, 1202-1209
82. Mujtaba, S.; He, Y.; Zeng, L.; Yan, S.; Plotnikova, O.; Sachchidanand; Sanchez, R.; Zeleznik-Le, N.; Ronai, Z.; Zhou, M. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation Mol. Cell 2004, 13, 251-263
83. Sachchidanand; Resnick-Silverman, L.; Yan, S.; Mutjaba, S.; Liu, W.-J.; Zeng, L.; Manfredi, J. J.; Zhou, M.-M. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association Chem. Biol. 2006, 13, 81-90
84. Borah, J. C.; Mujtaba, S.; Karakikes, I.; Zeng, L.; Muller, M.; Patel, J.; Moshkina, N.; Morohashi, K.; Zhang, W.; Gerona-Navarro, G.; Hajjar, R. J.; Zhou, M.-M. A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes Chem. Biol. 2011, 18, 531-541
85. Zeng, L.; Zhang, Q.; Gerona-Navarro, G.; Moshkina, N.; Zhou, M.-M. Structural basis of site-specific histone recognition by the bromodomains of human coactivators PCAF and CBP/p300 Structure 2008, 16, 643-652
86. Gerona-Navarro, G.; Yoel-Rodríguez; Mujtaba, S.; Frasca, A.; Patel, J.; Zeng, L.; Plotnikov, A. N.; Osman, R.; Zhou, M.-M. Rational design of cyclic peptide modulators of the transcriptional coactivator CBP: a new class of p53 inhibitors J. Am. Chem. Soc. 2011, 133, 2040-2043
87. Charlop-Powers, Z.; Zeng, L.; Zhang, Q.; Zhou, M.-M. Structural insights into selective histone H3 recognition by the human polybromo bromodomain 2 Cell Res. 2010, 20, 529-538
88. Sasaki, K.; Ito, T.; Nishino, N.; Khochbin, S.; Yoshida, M. Real-time imaging of histone H4 hyperacetylation in living cells Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 16257-16262